Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Cash from Restructuring (2017 - 2018)

Historic Cash from Restructuring for Cardiff Oncology (CRDF) over the last 2 years, with Q2 2018 value amounting to $187500.0.

  • Cardiff Oncology's Cash from Restructuring changed N/A to $187500.0 in Q2 2018 from the same period last year, while for Sep 2019 it was $187500.0, marking a year-over-year decrease of 3583.16%. This contributed to the annual value of $34000.0 for FY2020, which is N/A changed from last year.
  • Per Cardiff Oncology's latest filing, its Cash from Restructuring stood at $187500.0 for Q2 2018.
  • In the past 5 years, Cardiff Oncology's Cash from Restructuring ranged from a high of $485000.0 in Q1 2017 and a low of $104700.0 during Q4 2017